Viridian Therapeutics partners with Kissei Pharmaceutical to develop and market veligrotug and VRDN-003 in Japan. The deal includes a $70 million upfront payment and potential milestone payments totaling up to $315 million, along with tiered royalties on net sales. Kissei will lead development, regulatory, and commercialization efforts in Japan for these anti-IGF-1R antibodies targeting thyroid eye disease. VRDN-003 is a subcutaneous, half-life extended version of veligrotug, positioning it as a potential best-in-class therapy. In pre-market trading, Viridian Therapeutics is down 0.18% at $16.76 on the Nasdaq.

Read more at Nasdaq: Viridian Partners With Kissei In $385 Mln Japan Deal For Thyroid Eye Disease Treatments